Australien - engelska - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - chloral hydrate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; saccharin sodium; glycerol; methyl hydroxybenzoate; ethanol; propylene glycol; purified water; flavour - indications as at 19 september 2003: chloral hydrate mixture is indicated pre-operatively to produce sedation. it is also indicated for short term (not more than 2 weeks) use as a hypnotic to assist in sleep disorders.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

marlborough pharmaceuticals ltd - chloral hydrate - oral solution - 28.66mg/1ml

Australien - engelska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: dl-alpha-tocopherol; ethanol; corn glycerides; propylene glycol; peg-40 hydrogenated castor oil - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cystostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see warnings). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. additional indication from 11 june 1997: for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.

USA - engelska - NLM (National Library of Medicine)

ascend laboratories, llc - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days.  dabigatran etexilate capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. dabigatran etexilate capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery.  pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules is contraindic

USA - engelska - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: • active pathological bleeding [see warnings and precautions ( 5.2) and adverse reactions ( 6.1)] • history of a seri

USA - engelska - NLM (National Library of Medicine)

american health packaging - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] - history of a serious hypersensitivity

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - levomenthol; squill tincture; liquorice liquid extract - oral solution - 800microgram/1ml ; 120microlitre/1ml ; 25microlitre/1ml

Australien - engelska - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - chloral hydrate, quantity: 50 mg/ml - oral liquid, solution - excipient ingredients: glycerol; sucrose; anise oil; ethanol; methyl hydroxybenzoate; saccharin sodium; citric acid; purified water; flavour - indications as at 19 september 2003: chloral hydrate mixture is indicated pre-operatively to produce sedation. it is also indicated for short term (not more than 2 weeks) use as a hypnotic to assist in sleep disorders.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

mcneil products ltd - guaifenesin; levomenthol - oral solution - 20mg/1ml ; 220microgram/1ml

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - chloral hydrate - oral solution - 28.66mg/1ml